EUVIMEDObjevte EUVIMED
FallberichtOpen access · CC BY-NC 4.0

Case Series of Patients With FGFR1 ‐Related Pheochromocytoma and Paraganglioma With a Focus on Biochemical, Imaging Signatures and Treatment Options

Sakshi Jhawar, Abhishek Jha, Sara Talvacchio, Junne Kamihara, Jaydira Del Rivero, Karel Pacak

Clinical Endocrinology · 2025-06 · 102 (6) · 626-634

DOI: 10.1111/cen.15212 ↗

At a glance

Fallbericht in Clinical Endocrinology, published online on 2025-03-17. Written by Sakshi Jhawar and 5 co-authors. Institution: National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland, USA. Major MEDLINE topics: Adrenal Gland Neoplasms, Paraganglioma, Pheochromocytoma, Receptor, Fibroblast Growth Factor, Type 1. Cited 3 times so far (Crossref); 50 references. The full text is freely available (open access, CC BY-NC 4.0).

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

Pheochromocytoma and paraganglioma (together PPGL) are tumours with a high degree of heritability. Genetic landscape is divided into three clusters, cluster 1 (Krebs/pseudohypoxia signalling pathway), cluster 2 (kinase signalling pathway) and cluster 3 (Wnt signalling pathway). With increasing knowledge in the field of genetics, cluster‐specific tumour characteristics, biochemical phenotype and imaging signatures are established in commonly found genes. The association of FGFR1 pathogenic mutations with PPGL have been recently described although its features are not yet well established. Here, we present four patients with PPGL who were found to have somatic FGFR1 pathogenic mutations. We discuss their clinical presentations, biochemical phenotypes, imaging signatures and treatment options that will be relevant for practicing physicians in managing these patients effectively.

Subjects

MeSH terms (MEDLINE)

Adrenal Gland NeoplasmsParagangliomaPheochromocytomaReceptor, Fibroblast Growth Factor, Type 1HumansMutation

Author keywords

FGFR1biochemical phenotypegeneticsimaging phenotypeparagangliomapheochromocytoma

Substances

FGFR1 protein, humanReceptor, Fibroblast Growth Factor, Type 1

Authors and institutions

  • National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland, USA.
  • Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland, USA.
  • Dana-Farber/Boston Children's Cancer and Blood Disorders Center and Harvard Medical School, Boston, Massachusetts, USA.
  • National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.

Cite

APA

Jhawar, S., Jha, A., Talvacchio, S., Kamihara, J., Del Rivero, J., & Pacak, K. (2025). Case Series of Patients With FGFR1 ‐Related Pheochromocytoma and Paraganglioma With a Focus on Biochemical, Imaging Signatures and Treatment Options. Clinical Endocrinology, 102(6), 626-634. https://doi.org/10.1111/cen.15212

Vancouver

Jhawar S, Jha A, Talvacchio S, Kamihara J, Del Rivero J, Pacak K. Case Series of Patients With FGFR1 ‐Related Pheochromocytoma and Paraganglioma With a Focus on Biochemical, Imaging Signatures and Treatment Options. Clinical Endocrinology. 2025;102(6):626-634. doi:10.1111/cen.15212

BibTeX
@article{Jhawar2025,
  author = {Jhawar, Sakshi and Jha, Abhishek and Talvacchio, Sara and Kamihara, Junne and Del Rivero, Jaydira and Pacak, Karel},
  title = {Case Series of Patients With FGFR1 ‐Related Pheochromocytoma and Paraganglioma With a Focus on Biochemical, Imaging Signatures and Treatment Options},
  journal = {Clinical Endocrinology},
  year = {2025},
  volume = {102},
  number = {6},
  pages = {626--634},
  doi = {10.1111/cen.15212}
}
Start for free →